AI Signal Dashboard
Last updated: 04.30 08:05
Top Undervalued
+1.5¢
(Yes)
FDA approves argenx's Vyvgart? AI analysis: • +1.5¢ undervalued • Live Prediction Market fair value & mispricing alerts.
Undervalued Options Insights:
Argenx's Vyvgart (efgartigimod) is already approved and has strong data in myasthenia gravis. The cu...
🔓 Log in to see more
Real-time High Yield Opportunities
View MoreAll
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
83.5¢
16.5¢
85¢
15¢
+1.5¢
0¢
⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.
Hedging
ARGX
This event directly determines the label expansion for Argenx's (ARGX) flagship product, Vyvgart. An unexpected rejection (Complete Response Letter) would severely impact future revenue projections, likely causing a massive double-digit swing in the stock. Thus, this market serves as a direct event-driven hedge for ARGX equity.